Literature DB >> 16611218

Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein.

Jeroen van Bergeijk1, Kirsten Haastert, Claudia Grothe, Peter Claus.   

Abstract

Spinal muscular atrophy (SMA) is a neurodegenerative disorder of motoneurons. The disease is caused by deletions or mutations of the survival of motoneuron gene 1 (SMN1). The amount of protein expressed from the second gene, SMN2, correlated with the severity of the clinical phenotype. The histone deacetylase inhibitor valproic acid (VPA) has been shown to increase the total cellular amount of functional SMN protein and is therefore considered as a drug candidate for treatment of SMA. In this study, we analyzed the effects of VPA in PC12 cells, a model system for neuronal differentiation, with regard to neurite outgrowth and SMN expression. VPA promoted neurite outgrowth in PC12 cells. However, this effect did not correlate with upregulation of SMN protein levels, suggesting a SMN-independent mechanism for VPA regulation of neurite outgrowth.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611218     DOI: 10.1111/j.1747-0285.2006.00369.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  17 in total

1.  Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro.

Authors:  Lei Lv; Xiang Han; Yan Sun; Xin Wang; Qiang Dong
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

2.  SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 3.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

4.  SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy.

Authors:  John T Kissel; Bakri Elsheikh; Wendy M King; Miriam Freimer; Charles B Scott; Stephen J Kolb; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2014-02       Impact factor: 3.217

5.  Survival motor neuron protein regulates apoptosis in an in vitro model of spinal muscular atrophy.

Authors:  Graham C Parker; Xingli Li; Roumen A Anguelov; Gabor Toth; Adam Cristescu; Gyula Acsadi
Journal:  Neurotox Res       Date:  2008-01       Impact factor: 3.911

6.  Decreased GFAP expression and improved functional recovery in contused spinal cord of rats following valproic acid therapy.

Authors:  Marzieh Darvishi; Taki Tiraihi; Seyed A Mesbah-Namin; AliReza Delshad; Taher Taheri
Journal:  Neurochem Res       Date:  2014-09-10       Impact factor: 3.996

7.  Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice.

Authors:  Li-Kai Tsai; Ming-Shiun Tsai; Chen-Hung Ting; Hung Li
Journal:  J Mol Med (Berl)       Date:  2008-07-23       Impact factor: 4.599

8.  Regulation of neurite growth by inorganic pyrophosphatase 1 via JNK dephosphorylation.

Authors:  Yu Tezuka; Mizuki Okada; Yuka Tada; Junji Yamauchi; Hideo Nishigori; Atsushi Sanbe
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.

Authors:  John T Kissel; Charles B Scott; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; Kathryn J Swoboda
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

10.  Phase II open label study of valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Sandra P Reyna; Thomas W Prior; Bernard LaSalle; Susan L Sorenson; Janine Wood; Gyula Acsadi; Thomas O Crawford; John T Kissel; Kristin J Krosschell; Guy D'Anjou; Mark B Bromberg; Mary K Schroth; Gary M Chan; Bakri Elsheikh; Louise R Simard
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.